Equity Partners Ii Llccanaa... Net Worth

The estimated Net Worth of Equity Partners Ii Llccanaa... is at least $154 Million dollars as of 10 November 2005. Equity Llccanaa owns over 1,053,000 units of Dexcom Inc stock worth over $139,722,278 and over the last 19 years Equity sold DXCM stock worth over $14,004,900.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Equity Llccanaa DXCM stock SEC Form 4 insiders trading

Equity has made over 1 trades of the Dexcom Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Equity sold 1,053,000 units of DXCM stock worth $14,004,900 on 10 November 2005.

The largest trade Equity's ever made was selling 1,053,000 units of Dexcom Inc stock on 10 November 2005 worth over $14,004,900. On average, Equity trades about 526,500 units every 0 days since 2005. As of 10 November 2005 Equity still owns at least 2,040,635 units of Dexcom Inc stock.

You can see the complete history of Equity Llccanaa stock trades at the bottom of the page.

Insiders trading at Dexcom Inc

Over the last 19 years, insiders at Dexcom Inc have traded over $724,717,982 worth of Dexcom Inc stock and bought 165,450 units worth $3,489,100 . The most active insiders traders include Sean Carney, Kim D Blickenstaff, and Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of $892,438. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth $29,458.

What does Dexcom Inc do?

founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.

Complete history of Equity Llccanaa stock trades at Dexcom Inc

Dexcom Inc executives and stock owners

Dexcom Inc executives and other stock owners filed with the SEC include:

• Kevin Sayer,
  Chairman of the Board, President, Chief Executive Officer
• Quentin Blackford,
  Chief Financial Officer, Chief Operating Officer
• Richard Doubleday,
  Executive Vice President, Chief Commercial Officer
• Andrew Balo,
  Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development
• Steven Pacelli,
  Executive Vice President - Strategy and Corporate Development
• Donald Abbey,
  Executive Vice President - Quality and Regulatory Affairs
• Kevin Ronald Sayer,
  Exec. Chairman, CEO & Pres
• Jacob Steven Leach,
  Exec. VP & CTO
• Bridgette Heller,
  Independent Director
• Mark Foletta,
  Lead Independent Director
• Eric Topol,
  Independent Director
• Jay Skyler,
  Independent Director
• Nicholas Augustinos,
  Independent Director
• Steven Altman,
  Independent Director
• Barbara Kahn,
  Independent Director
• Richard Collins,
  Independent Director
• Kyle Malady,
  Independent Director
• Karen Dahut,
  Independent Director
• Shelly Selvaraj,
  Senior Vice President - Information Technology
• Jeffrey Moy,
  Senior Vice President - Operations
• Jereme Sylvain,
  Senior Vice President - Finance, Chief Accounting Officer
• Patrick Murphy,
  Executive Vice President, Chief Legal Officer
• Jake Leach,
  Executive Vice President, Chief Technology Officer
• Shelly Ramasamy Selvaraj,
  Sr. VP of Information Technology
• Donald M. Abbey,
  Exec. VP of Global Bus. Services, IT, Quality & Regulatory Affairs
• Steven R. Pacelli,
  Exec. VP & MD of Dexcom Ventures
• Andrew K. Balo,
  Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel.
• Sadie M. Stern,
  Exec. VP & Chief HR Officer
• Chad M. Patterson,
  Exec. VP of Global Marketing
• Sean Christensen,
  Director of Corp. Affairs & Head of Investor Relations
• Jereme M. Sylvain,
  Exec. VP, CFO & Chief Accounting Officer
• John Lister,
  VP, Legal Affairs
• Terrance H Gregg,
  Director
• Jess Roper,
  VP, CFO
• Jorge A Valdes,
  Vice President of Engineering
• Girish Naganathan,
  EVP Chief Technology Officer
• Heather S Ace,
  SVP Human Resources
• Kevin M Sun,
  VP, Corp Controller & Treasury
• Jonathan T Md Lord,
  Director
• Glen D Nelson,
  Director
• Peter Gerhardsson,
  VP, Int'l Business Development
• David Carner,
  VP, Quality Assurance
• Laura Johnson,
  V.P., Intellectual Property
• Martin Doordan,
  Director
• Sean Carney,
  Director
• John Riolo,
  VP of Quality Assurance
• Claudia Graham,
  VP, Marketing
• Donald A Lucas,
  Director
• Donald L Lucas,
  Director
• Mark Brister,
  VP, Advanced Development Teams
• Richard Yang,
  V.P., Strategic Affairs
• James H Brauker,
  VP, Research & Development
• Rodney L Kellogg,
  Vice President of Sales
• Andrew P Rasdal,
  President and CEO
• Steven J Kemper,
  Chief Financial Officer
• Kim D Blickenstaff,
  Director
• Tae Andrews,
  Vice President of Marketing
• Paul Travelers Companies In...,
  
• Pincus Private Equity Viii ...,
  
• Brenton Karl Ahrens,
  Director
• Nancy Sfog City Management ...,
  
• Equity Partners Ii Llccanaa...,
  
• Paul Travelers Companies In...,
  
• Eric A Charmers Landing Llc...,
  
• Scott Lwindamere Llcwindame...,
  
• Equity Partners Ii Llc Waub...,
  
• Teri L Lawver,
  EVP Chief Commercial Officer
• Paul R Flynn,
  EVP Global Revenue
• Matthew Vincent Dolan,
  EVP Strategy and Corporate Dev
• Sumi Shrishrimal,
  SVP Chief Risk Officer
• Chad Patterson,
  EVP Global Marketing
• Barry J. Regan,
  EVP Operations
• Jacob Steven Leach,
  EVP, Chief Operating Officer
• Rimma Driscoll,
  Director
• Michael Jon Brown,
  EVP, Chief Legal Officer
• Sadie Stern,
  EVP, Chief HR Officer